Stevanato Group Posts 8% Q2 Revenue Growth, Boosts Full-Year Outlook
STVN sits 60% above its 52-week low of $12.89 on elevated volume (2.1× avg).
Summary
Stevanato Group reported strong second-quarter 2026 results, with revenue up 8% to €302.0 million and adjusted EBITDA margin expanding 280 basis points to 26.0%. Adjusted diluted EPS increased to €0.14. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, while narrowing its adjusted diluted EPS outlook, citing better currency translation and organic growth. This positive update follows the recent European marketing authorizations for its Alina® pen injector platform, which the CEO emphasized. The company also completed the divestiture of its Balda C. Brewer subsidiary, incurring a €12.2 million expense, but expects the sale to be accretive to full-year margins.
At the time of this announcement, STVN was trading at $20.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $12.89 to $28.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.